Overview

Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

Status:
NOT_YET_RECRUITING
Trial end date:
2027-03-07
Target enrollment:
Participant gender:
Summary
To learn if olverembatinib can help to control newly diagnosed CML in the chronic phase.
Phase:
PHASE2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Ascentage Pharma Group Inc.
Treatments:
olverembatinib